文献速递类风湿关节炎

中性粒细胞-淋巴细胞比值在早期类风湿关节炎中预测三联治疗失败的能力

The neutrophil-lymphocyte ratio in early rheumatoid arthritis and its ability to predict subsequent failure of triple therapy.
PubMed 文献 · Semin Arthritis Rheum · 2019-05-31

本研究在早期类风湿关节炎患者中评估中性粒细胞-淋巴细胞比值(NLR)和血小板-淋巴细胞比值(PLR)能否预测因疾病持续活动而需升级改善病情抗风湿药(DMARD)治疗。

要点

  • 基线NLR>2.7是早期RA患者12个月三联治疗失败的独立预测因素(OR 2.65)。
  • NLR对三联治疗失败的预测优于PLR、ESR、CRP和DAS28ESR。
  • NLR可能作为廉价、客观、可重复的RA预后标志物。

核心结论

  • NLR在随后三联治疗失败的RA患者中显著升高,且预测能力优于传统疾病活动标志物。

研究设计与样本

  • 研究纳入皇家阿德莱德医院早期关节炎门诊新诊断的RA患者,所有患者按标准化方案开始甲氨蝶呤、柳氮磺吡啶和羟氯喹三联治疗,每3至6周复查,未达低疾病活动度则按预设算法调整DMARD。

主要发现

  • 三联治疗失败者基线平均NLR显著高于未失败者(3.7±2.8 vs. 2.9±1.5;p=0.02),而PLR无显著差异。

关键数值与推荐

  • 主要结局指标为12个月时三联治疗未能维持低疾病活动度(DAS28<3.2)。

临床怎么用

  • 基线NLR>2.7可能提示早期RA患者三联治疗失败风险较高,可辅助临床决策。
  • NLR作为廉价、客观、可重复的标志物,有望用于指导RA管理,但需进一步研究确认。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess whether the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) can predict those who subsequently require escalation of disease modifying therapy because of continued disease activity in rheumatoid arthritis (RA). METHODS: Patients with newly diagnosed RA were recruited from the Early Arthritis Clinic at the Royal Adelaide Hospital. All patients commenced "triple-therapy" with a standardised protocol of methotrexate, sulfasalazine and hydroxychloroquine, and were reviewed every three to six weeks. DMARD therapy was adjusted according to a pre-defined algorithm if not in low disease activity. The NLR, PLR and other markers of disease activity including ESR, CRP and DAS28 were collected, as well as current therapy. The primary outcome measure was failure of triple-therapy to maintain low-disease activity (DAS28<3.2) at 12 months. RESULTS: Two-hundred and twenty-two patients met inclusion criteria. The mean age was 54.2 ± 15.4 years, with a mean disease duration of 22.3 ± 25.0 weeks. Forty-five (20%) patients had failed triple therapy by one year. The mean baseline NLR was significantly higher in those who failed triple therapy compared with those who did not (3.7 ± 2.8 vs. 2.9 ± 1.5; p = 0.02), however, the PLR was not significantly different. A baseline NLR>2.7 was an independent predictor of treatment failure (OR 2.65, CI 1.23-5.72, p = 0.01) whilst the PLR, ESR, CRP and DAS-28ESR were not. CONCLUSION: The NLR is significantly increased in those who subsequently fail triple-therapy for RA, and it outperformed conventional markers of disease activity. The NLR may offer an inexpensive, objective and reproducible prognostic marker in RA. Further studies are justified to confirm its potential role in guiding the management of RA.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Boulos D, Proudman SM, Metcalf RG, et al. The neutrophil-lymphocyte ratio in early rheumatoid arthritis and its ability to predict subsequent failure of triple therapy. Semin Arthritis Rheum. 2019. PMID: 31248587. doi:10.1016/j.semarthrit.2019.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。